

Quantitative Attribution of the Protective Effects of Aminosterols against Protein Aggregates to Their Chemical Structures and Ability to Modulate Biological Membranes

Silvia Errico, Giacomo Lucchesi, Davide Odino, Enass Youssef Osman, Roberta Cascella, Lorenzo Neri, Claudia Capitini, Martino Calamai, Francesco Bemporad, Cristina Cecchi, William A. Kinney, Denise Barbut, Annalisa Relini, Claudio Canale, Gabriella Caminati, Ryan Limbocker, Michele Vendruscolo, Michael Zasloff, and Fabrizio Chiti*



Cite This: *J. Med. Chem.* 2023, 66, 9519–9536



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: Natural aminosterols are promising drug candidates against neurodegenerative diseases, like Alzheimer and Parkinson, and one relevant protective mechanism occurs via their binding to biological membranes and displacement or binding inhibition of amyloidogenic proteins and their cytotoxic oligomers. We compared three chemically different aminosterols, finding that they exhibited different (i) binding affinities, (ii) charge neutralizations, (iii) mechanical reinforcements, and (iv) key lipid redistributions within membranes of reconstituted liposomes. They also had different potencies (EC_{50}) in protecting cultured cell membranes against amyloid- β oligomers. A global fitting analysis led to an analytical equation describing quantitatively the protective effects of aminosterols as a function of their concentration and relevant membrane effects. The analysis correlates aminosterol-mediated protection with well-defined chemical moieties, including the polyamine group inducing a partial membrane-neutralizing effect ($79 \pm 7\%$) and the cholestane-like tail causing lipid redistribution and bilayer mechanical resistance ($21 \pm 7\%$), linking quantitatively their chemistry to their protective effects on biological membranes.



INTRODUCTION

Many of the most severe neurodegenerative diseases originate from the conversion of specific polypeptide chains from their native soluble states into amyloid aggregates, forming various types of extracellular deposits or intracellular filaments, including amyloid plaques by the amyloid- β ($A\beta$) peptide, neurofibrillary tangles by the tau protein, Lewy bodies by α -synuclein (αS), amyloid plaques by the prion protein (PrP^{Sc}), and numerous others.^{1,2} Their corresponding disorders are Alzheimer's disease (AD), frontotemporal dementia (FTD), Parkinson's disease (PD), spongiform encephalopathies (SE), and many other pathologies.^{1,2} Key pathogenic species in these disorders are thought to be small oligomeric species. These transient aggregates form both during the process of amyloid fibril formation and upon their release from mature fibrils, and oligomers are able to interact with a number of molecular targets, including biological membranes, giving rise to a cascade of dysfunctional events.^{1,3}

Aminosterols (AMs) isolated from the dogfish shark *Squalus acanthias* have been increasingly shown to change amyloid fibril formation for $A\beta$ and αS dramatically^{4–6} and inhibit the

interaction of amyloidogenic proteins with biological membranes, both in their monomeric and oligomeric forms,^{4–9} thus representing putative drug candidates against AD, PD, and possibly other neurodegenerative conditions.¹⁰ In particular, two of them have been shown to decrease significantly, or even eliminate, the toxicity of misfolded αS or $A\beta$ oligomers in cell cultures and *C. elegans* models of PD and AD by interacting with cell membranes and either preventing the binding or displacing oligomers from the plasma membrane.^{4–8} AMs have also been shown to bind to the lipid bilayer of membrane liposomes^{9,11} and exert their monomer/oligomer displacement or binding inhibition effect even on such reconstituted systems devoid of proteins,^{4–6,9} suggesting that they mediate their effect through membrane bilayer binding. AMs were not found

Received: February 2, 2023

Published: July 11, 2023






Figure 1. Structural formulas of the three AMs investigated in this work, and mode of membrane insertion and perturbation for TRO. (A) Chemical structures of TRO (blue), SQ (red), and ENT-03 (green). (B) Schematic representation of the insertion and localization of TRO within biological membranes, as previously determined experimentally.¹¹ The 55° angle refers to the whole molecule, rather than the steroid group or polyamine group only. The 14.8 ± 0.2 and 5.6 ± 0.2 Å distances refer to the space occupied by the molecule and portion sticking out of the membrane along the normal to the bilayer plane, respectively. (C) Schematic representation of the three major physico-chemical effects on cell membranes induced by the insertion of TRO, all possibly mediating the TRO-induced protection against the toxicity of misfolded protein oligomers.¹¹

to bind to oligomers in a way that alters their morphology and structure at concentrations where they exhibit membrane binding and cell protection,^{7,8,10} ruling out that oligomer-AM binding is responsible for the AM-mediated inhibition of oligomer-membrane binding.

These compounds are known as squalamine (SQ) and trodusquemine (TRO), which are also known as ENT-01 and MSI-1436, respectively (Figure 1A). In mouse models of PD and in wild-type aged mice, SQ has been found to restore excitability within the enteric neurons and to restore normal colonic motility.^{12,13} SQ (in the form of its phosphate salt, ENT-01) has just completed a multicenter, randomized, double-blind, placebo-controlled phase-2b clinical trial in patients with PD-related constipation (KARMET, identifier NCT03781791) and shown improvement in constipation as well as hallucinations and dementia.¹⁴ A previous multicenter,

open label phase 2 study in patients with Parkinson's disease (RASMET, identifier NCT03938922) had also shown improvement in constipation, sleep, REM-behavior disorder, hallucinations, and dementia.¹⁵ Both TRO and SQ have passed phase 1 clinical trials showing good safety and tolerability (Identifiers: NCT00606112 and NCT00139282, respectively).

The interaction of AMs with the lipid bilayer of biological membranes is, therefore, a central component in the mechanism by which these small molecules mediate their protection against amyloidogenic proteins and their misfolded oligomers. This interaction has been mainly investigated, at the physicochemical and molecular levels, using TRO and liposomes in the form of large unilamellar vesicles (LUVs) as a model of the lipid bilayer of the cell membrane.^{10,11} TRO was reported to stably insert into the hydrophilic portion of the first upper layer of the membrane, down to the interface




Figure 2. Changes in fluorescence anisotropy and emission of the three fluorescently labeled AMs in the presence of LUVs. (A, B) Fluorescence anisotropy (r) values at 570 nm for BODIPY (A) and at 617 nm for A594 (B), of 10 μ M L-Arg (gray), TRO (blue), SQ (red), and ENT-03 (green) labeled with BODIPY (A) and A594 (B), obtained in the absence and presence of 0.5 mg/mL LUVs. (C, D) Fluorescence emission corresponding to the integrated area between 550–650 nm for BODIPY (C) and 600–700 nm for A594 (D), of 10 μ M L-Arg (gray), TRO (blue), SQ (red), and ENT-03 (green) labeled with BODIPY (C) and A594 (D), obtained in the absence and presence of 0.5 mg/mL LUVs. Bars indicate mean \pm SEM ($n = 5$. n.s., nonsignificant; ***, $p < 0.001$ relative to corresponding values in the absence of LUVs (Student's t -test).

between the hydrophilic and hydrophobic portions, exposing both sulfate and spermine groups to the aqueous phase (Figure 1B).¹¹ The molecule digs into the membrane by 9.2 ± 0.2 Å, with an angle of 55° , and has its spermine moiety sticking out of the membrane by 5.6 ± 0.2 Å, occupying a total length of 14.8 ± 0.2 Å along the axis perpendicular to the bilayer plane (Figure 1B). The insertion of TRO in lipid bilayers leads to three main physicochemical perturbations of the membrane (Figure 1C): (i) a decrease of the total negative charge, (ii) an increase of the mechanical resistance to indentation, and (iii) a reorganization of the spatial distribution of both cholesterol (CHOL) and monosialotetrahexosylganglioside 1 (GM1) lipids, clustering CHOL molecules, clustering GM1 molecules, and separating CHOL from GM1.¹¹ These three known perturbations have been postulated to reinforce biological membranes against the toxic action of protein misfolded oligomers.

In spite of these recent advances, it is not yet clear which of the three aforementioned changes of the membrane bilayer induced by AMs are the most effective in mediating their protective role and if all of them are relevant. Moreover, it remains to be elucidated which of the chemical moieties of the

AMs are mainly involved in mediating their protection. These drawbacks limit our ability to predict the potency of other natural AMs and to anticipate the potency of other related or newly designed molecules. More generally, they limit our understanding of the relationship between the chemistry of small molecules, the physicochemical status of the cell membrane, and the toxicity of misfolded oligomers, thereby hindering the search of generic strategies to protect cell membranes from the action of deleterious protein oligomers.

In this work, we compare three different chemically synthesized AMs, characterized by different chemical and structural formulas. We compare, in particular, SQ, TRO, and ENT-03, the latter of which is an AM recently identified in the mouse *Mus musculus*,¹⁶ whereas TRO and SQ were originally isolated from the dogfish shark *Squalus acanthias*.^{17,18} The three AMs share a sterol group, an alkyl moiety of the cholestane-type fused to the sterol at C-17, and an alkyl polyamine tail fused to the sterol at C-3 and replacing the hydroxyl group (Figure 1A), as previously described.^{16–18} However, the three AMs differ because of a sulfate moiety at position 24 for SQ and TRO, and a carboxylate group replacing the methyl group at position C-25 for ENT-03

Table 1. Fluorescence Anisotropy and Intensity of AMs Incubated with LUVs^a

AM	r (– LUVs)	r (+ LUVs)	fluorescence (– LUVs) (a.u.)	fluorescence (+ LUVs) (a.u.)	K_D (mg/mL)	K_D (μ M)
L-Arg-BODIPY	0.0155 \pm 0.0004	0.0595 \pm 0.0016	3994 \pm 8	3964 \pm 87		
TRO-BODIPY	0.0271 \pm 0.0008	0.2173 \pm 0.0033	4010 \pm 8	8828 \pm 154	0.0302 \pm 0.0032	38.7 \pm 4.1
SQ-BODIPY	0.0289 \pm 0.0009	0.2221 \pm 0.0038	4136 \pm 51	19,358 \pm 635	0.0169 \pm 0.0023	21.6 \pm 2.9
ENT-03-BODIPY	0.0258 \pm 0.0010	0.2296 \pm 0.0017	3994 \pm 15	6435 \pm 201	0.0321 \pm 0.0064	41.1 \pm 8.2
L-Arg-A594	0.0294 \pm 0.0007	0.0302 \pm 0.0007	4085 \pm 7	4141 \pm 63		
TRO-A594	0.0493 \pm 0.0009	0.1630 \pm 0.0020	4483 \pm 29	8471 \pm 779	0.1516 \pm 0.0545	195 \pm 70
SQ-A594	0.0440 \pm 0.0025	0.2349 \pm 0.0014	4678 \pm 23	16,612 \pm 1431	0.0620 \pm 0.0093	79 \pm 12
ENT-03-A594	0.0471 \pm 0.0014	0.1301 \pm 0.0057	4541 \pm 38	7304 \pm 362	0.1164 \pm 0.0603	148 \pm 81

^aAnisotropy (r) at 570 and 617 nm and intensity area between 550–650 and 600–700 nm for BODIPY and A594-labeled L-Arg and AMs, respectively, in the absence and in the presence of 0.5 mg/mL LUVs. K_D values obtained from the binding experiments expressed in mg/mL and μ M of total lipids. Experimental errors are standard error of the mean (SEM) of $n = 5$ technical replicates.




Figure 3. Binding of the three AMs to LUVs. Binding plots reporting the fluorescence emission at 572 nm (A) and 612 nm (B), of 10 μ M BODIPY (A) and A594 (B) labeled TRO (blue), SQ (red), ENT-03 (green), and L-Arg (gray) versus LUV concentration. The lines through the data points represent the best fits to eq 6. Each graph reports the obtained K_D value in units of mg/mL and μ M of total lipids. Experimental errors are SEM ($n = 5$).

(Figure 1A). They also differ for the alkyl polyamine group, which is a spermidine for SQ (7 methylene and 3 amino groups) and a spermine for TRO and ENT-03 (10 methylene and 4 amino groups), resulting in a higher net positive charge by one unit relative to SQ (Figure 1A). Herein, we demonstrate that the three AMs bind to cell membranes with different affinities, affect the physicochemical and molecular properties of the lipid bilayer to different extents, and result in different protective effects, raising an opportunity to compare these different aspects at the chemical and physical levels. We then relate all these chemical, physical, molecular, and biological measurables using an approach of quantitative chemical biology that led to the precise identification and quantification of: (i) the chemical groups within AMs mainly responsible for their protective effect, and (ii) the specific physicochemical changes of the membrane that most mediate this protective effect, both enriched with a predictive power.

RESULTS AND DISCUSSION

All Three AMs Bind to LUVs. To investigate whether TRO, SQ, and ENT-03 bind to LUVs, the fluorescence anisotropy (r) values of 10 μ M BODIPY TMR-X-labeled AM (AM-BODIPY) and Alexa Fluor 594-labeled AM (AM-A594) were measured in the absence and presence of 0.5 mg/mL LUVs incubated with the three AMs for 15 min. BODIPY and

A594 labeled the distal primary amino group of the polyamine chain, which is known to stick out of the membrane from previous studies on TRO¹¹ and is not expected, therefore, to affect the AM-membrane binding affinity significantly. In addition, the two probes have different chemical properties. BODIPY has a lower molecular weight, is hydrophobic, and has a neutral net charge, whereas A594 has a higher molecular weight, is hydrophilic, and has a negative net charge. These differences enable the assessment of whether the probe chemistry affects dramatically the LUV-AM binding affinity.

The incubation of all BODIPY-labeled AMs with LUVs showed a highly significant increment of r ($p < 0.001$, unpaired, two-tailed Student's t -test, Figure 2A, Table 1), suggesting a lower rotational freedom of the probe in the presence of LUVs. A similar result was obtained with A594-labeled AMs ($p < 0.001$, Figure 2B, Table 1). r values of 10 μ M L-Arg-BODIPY and L-Arg-A594, used here as negative controls of similarly labeled small molecules that have no predicted ability to bind to LUV bilayers, increased only marginally or did not increase significantly in the presence of LUVs (Figure 2A,B). L-Arg-BODIPY displayed a slight, but significant, increase of r when incubated with LUVs that was not reproduced with L-Arg-A594, possibly due to the hydrophobic nature of the BODIPY dye that caused clustering of L-Arg-BODIPY molecules or transient interactions with the




Figure 4. Light scattering intensity of LUVs in the presence of increasing concentrations of the three AMs. Plots reporting the square root of the light scattering intensity of LUVs with (I_{AM}) and without (I_{NO}) AM, respectively, versus AM concentration, representing the increase in LUV mass due to TRO (A), SQ (B), and ENT-03 (C) incorporation. The indicated AM concentrations correspond to the values reported on the x axis at saturation points. Experimental errors are SEM ($n = 3$).

membrane. We also investigated possible fluorescence emission changes of fluorescently labeled AMs (10 μ M) when incubated with LUVs (0.5 mg/mL) for 15 min (Figure 2C,D, Table 1). All AMs displayed a highly significant increase in fluorescence emission when incubated with LUVs, confirming their ability to bind to LUVs ($p < 0.001$). Notably, SQ labeled with both dyes showed a greater increase compared to the other two AMs, as noticed also for the r value of SQ-A594 ($p < 0.001$). This can be attributed to the shorter polyamine group of SQ relative to TRO and ENT-03, which reduces the distance of the dye probe from the membrane. Fluorescence of 10 μ M L-Arg-BODIPY and L-Arg-A594 did not change significantly upon LUV addition (Figure 2B,C, Table 1).

SQ Exhibits the Highest Affinity among the Three AMs for LUVs. Since all three labeled AMs increase their fluorescence upon LUV binding, we exploited this spectroscopic property to obtain quantitative measurements of the affinity of the three labeled AMs for LUVs. They were therefore incubated for 15 min (10 μ M) with increasing concentrations of unlabeled LUVs and we observed in all cases a significant increase in fluorescence emission (Figure 3). By fitting the data points to a standard binding curve (eq 6), it was possible to obtain K_D values of all labeled AMs (Figure 3, Table 1). With both fluorescent dyes, SQ confirmed the highest increase of fluorescence upon LUV binding and also showed a K_D value approximately 2-fold lower relative to the other two AMs, ($p < 0.05$), indicating a higher affinity for LUVs compared to the other two AMs. This observation can be attributed to the shorter hydrophilic spermidine moiety of SQ, as opposed to the longer hydrophilic spermine moiety of TRO and ENT-03, which increases the overall hydrophobicity of SQ and explains its higher affinity for LUVs. By contrast, TRO and ENT-03 displayed similar K_D values in both analyses with BODIPY and A594 ($p = 0.8198$ and $p = 0.7380$, respectively, nonsignificant).

The K_D value determined with BODIPY for a given AM was about 4-fold lower than that determined for the same AM with A594, indicating that the chemistry of the probe affects the AM-LUV affinity to some extent. However, the rankings and relative differences of the K_D values determined for the three AMs are similar when determined with either probe, indicating in both cases that TRO and ENT-03 have similar affinities for the LUV membrane, within experimental error, and that SQ

has a ca. 2-fold higher affinity. Since the two probes add a hydrophilic and hydrophobic component to the AMs, it is likely that the binding constant of a given unlabeled AM is intermediate between these two values. Negative controls with labeled L-Arg and increasing concentrations of LUVs showed the lack of variation in fluorescence, confirming that the binding abilities of labeled AMs to LUVs were mediated by the AM rather than the fluorescent probe bound to them (Figure 3).

To explore the kinetics of the AM-LUV binding, TRO-A594 as a representative AM and LUVs were rapidly mixed using a stopped-flow apparatus to final concentrations of 10 μ M and 0.5 mg/mL, respectively, and the TRO-A594 fluorescence change during the binding process was monitored in real time (Figure S1A). Two kinetic phases were observed, occurring on the time scales of ca. 500 ms and 10 s, respectively, therefore indicating that the binding was very rapid and that, after a time of 15 min explored here, binding has attained equilibrium. This holds true even at the lowest LUV concentration (0.12 mg/mL) tested (Figure S1B,C). These two phases may either represent the signature of a two-step binding mechanism or reflect two ligand subpopulations that bind LUVs with different kinetics. Assignment of the two phases to well defined molecular events is beyond the scope of the present analysis.

SQ Exhibits the Lowest Occupancy within LUVs among the Three AMs. The steric hindrance and chemical properties of the dyes bound to AMs could in principle have an impact on the interaction of AMs with LUVs. Therefore, we sought an additional experimental approach to probe the incorporation of TRO, SQ, and ENT-03 in their free unlabeled form with LUVs. To this aim, a light scattering analysis using only unlabeled species was carried out (0–100 μ M AMs, 0.5 mg/mL LUVs, 15 min). Since light scattering intensity is proportional to the second power of the mass of the light scattering particles, by incubating LUVs with increasing concentrations of the three AMs, it was possible to obtain a measure of the increase of LUV mass due to AM incorporation in these three cases (Figure 4).

All AMs induced an increase in light scattering intensity, and thus LUV mass, until a saturating concentration, after which they exhibited a plateau phase, where no more AMs were incorporated. SQ reached the plateau at a significantly lower concentration compared to the other AMs (Figure 4B, $p <$

0.05), whereas TRO and ENT-03 displayed similar saturating concentrations (Figure 4A,C, $p > 0.05$). The saturating concentrations were found to be 35 ± 7 , 12 ± 4 , and $43 \pm 5 \mu\text{M}$ for TRO, SQ, and ENT-03, respectively. These values can also be obtained from the LUV mass increase at saturation, which yields the mass of incorporated AMs, which were found to be 35 ± 4 , 15 ± 2 , and $43 \pm 4 \mu\text{M}$ for TRO, SQ, and ENT-03, respectively, in very good agreement with those estimated above. All AMs did not show a significant increment of LUV diameter (Figure S2), ruling out that the observed increase of light scattering intensity upon AM addition was due to an increase in LUV size. This analysis indicates that AMs bind to LUVs even without fluorescent labeling and allows the maximum AM occupancy to be estimated for all three AMs.

To obtain an independent estimate of the AM occupancy at LUVs at saturation, we employed a microfluidic technique using LUVs and TRO as a representative AM (Figure S3). We obtained a value of ca. $28\text{--}35 \mu\text{M}$ TRO at saturation, in agreement with the value of $35 \pm 4 \mu\text{M}$ TRO estimated with light scattering (Figure S3).

All Three AMs Partially Neutralize the Negative Charge of LUVs, with an Efficacy $\text{TRO} \cong \text{ENT-03} > \text{SQ}$.

Since $5 \mu\text{M}$ AM and 1.0 mg/mL LUVs are concentrations at which binding is complete (all AM is bound to LUVs, and LUVs are not yet saturated), we carried out the following analyses at these concentrations, in all cases after covesiculating AMs with the lipids of LUVs to rule out incomplete binding. In particular, we evaluated the effect of the three AMs on three physicochemical properties of the LUV lipid bilayer previously found to be altered by TRO and thought to represent important factors for the vulnerability of the lipid plasma membrane to misfolded protein oligomers:¹¹ the membrane negative charge, monitored with zeta potential (ζ) measurements, the resistance of the bilayer to a breakthrough force (BTF) perpendicular to the bilayer plane, monitored with supported lipid bilayers (SLBs) and atomic force microscopy (AFM), and the distribution of lipids in the membrane, monitored with lipid–lipid fluorescence resonance energy transfer (FRET).

The ζ was measured using naked LUVs and LUVs covesiculated with TRO, SQ, or ENT-03 (Figure 5A, Table 2). For naked LUVs, a negative value of ζ of $-23.6 \pm 0.7 \text{ mV}$ was found at $20 \text{ }^\circ\text{C}$,¹¹ whereas values of -18.7 ± 0.3 , -21.0 ± 0.5 , and $-18.7 \pm 0.3 \text{ mV}$ (mean \pm SEM) were obtained for LUVs covesiculated with TRO, SQ, and ENT-03, respectively, at the same temperature (Figure 5A, Table 2). These variations indicate, in all cases, a partial neutralization of the total negative surface charge of LUVs, or molecular packing of the charged lipid heads, upon AM addition ($p < 0.001$, $p < 0.05$, and $p < 0.001$, respectively). SQ induced a smaller decrease compared to TRO and ENT-03 ($p < 0.01$), which showed by contrast comparable decreases ($p > 0.05$). This is in agreement with the chemical properties of the three AMs, with SQ carrying a spermidine group, which is shorter and less positively charged than the spermine group of TRO and ENT-03.

ζ measurements versus temperature were then used to determine the phospholipid gel to liquid-crystalline phase transition temperature (T_m) of LUVs in the absence and presence of each AM (Figure 5A,B). The transition is described by a sharp change in the ζ potential (Figure 5A) that is more evident in corresponding first derivative plots (Figure 5B). The T_m of this LUV system is dominated by SM




Figure 5. The three AMs increase the transition temperatures of LUVs. (A) Zeta potential (ζ) and (B) fitted curves (left axis) and first derivative curves (right axis) of ζ values as a function of temperature for naked LUVs (black square), and AM-containing LUVs: TRO (blue), SQ (red), and ENT-03 (green). Experimental errors are standard deviations ($n = 5$). In each case, the T_m corresponds to the minimum of the first derivative curve.

(T_m of $35\text{--}40 \text{ }^\circ\text{C}$), since DOPC (T_m of $-17 \text{ }^\circ\text{C}$), which is the most abundant lipid, is already in a fluid-like phase in the examined temperature range.^{19,20} For naked LUVs, the T_m was observed at $24.5 \pm 2 \text{ }^\circ\text{C}$. All AMs induced an increase of the transition temperature of LUVs, up to values of $46 \pm 2 \text{ }^\circ\text{C}$ ($p < 0.01$), $35 \pm 2 \text{ }^\circ\text{C}$ ($p < 0.05$), and $46 \pm 2 \text{ }^\circ\text{C}$ ($p < 0.01$) with LUVs covesiculated with TRO, SQ, and ENT-03, respectively, indicating trend variations similarly to those measured with ζ at $20 \text{ }^\circ\text{C}$. The transition width is about $6 \text{ }^\circ\text{C}$ for the naked LUVs, but becomes larger with AM, up to $16 \text{ }^\circ\text{C}$ in the case of TRO-containing LUVs, confirming that AMs modify the packing of the bilayer and system disorder.²¹

All Three AMs Increase the Breakthrough Force of Supported Lipid Bilayers, with an Efficacy of $\text{TRO} > \text{SQ} > \text{ENT-03}$.

The resistance of the bilayer to a force applied perpendicular to its plane was analyzed by AFM, which allowed us to determine the breakthrough force (BTF) required to penetrate the bilayer with the AFM tip. Measurements were performed on SLBs in the absence and presence of each AM (Figure 6). As previously observed, SLBs with this lipid composition display the coexistence of two different phases: gel-phase domains ($L\beta$ or S_o), with possible contributions of liquid-ordered domains (L_o), enriched with SM, CHOL, and GM1, that float in a liquid-disordered phase ($L\alpha$ or L_d) enriched with DOPC.^{11,22} The largest fraction of breakthroughs was observed on $L\alpha$ regions, while most of the $L\beta$ regions displayed the absence of breakthrough events.¹¹ The presence of AMs determined an increase in BTF values

Table 2. Experimental Values of the Physicochemical Perturbations of the Membrane Induced by AMs^a

Parameter	ζ (mV)	$\Delta\zeta$ (%)	BTF (nN)	Δ BTF (%)	$r_{\text{GM1-CHOL}}$ (Å)	$\Delta r_{\text{GM1-CHOL}}$ (%)	$r_{\text{CHOL-CHOL}}$ (Å)	$\Delta r_{\text{CHOL-CHOL}}$ (%)
– AMs	-23.6 ± 0.7	0%	2.73 ± 0.09	0%	65 ± 1	0%	72 ± 1	0%
+ TRO	-18.7 ± 0.3	100%	4.2 ± 0.2	100%	79 ± 1	100%	58 ± 1	100%
+ SQ	-21.0 ± 0.5	53%	3.5 ± 0.2	52%	72 ± 1	50%	64 ± 1	57%
+ ENT-03	-18.7 ± 0.3	100%	3.0 ± 0.1	18%	73 ± 1	57%	63 ± 2	64%

^aZeta potential (ζ), breakthrough force (BTF), GM1/CHOL, and CHOL/CHOL mean shortest distance (r) experimental values, and their corresponding normalized percent values were obtained in the absence and presence of TRO, SQ, and ENT-03. BTF errors were evaluated as half of the range of variability of mean values from different series of measurements for each condition. Experimental r errors are SEM ($n = 3$ technical replicates). ζ potential errors are standard deviations ($n = 5$).

relative to AM-devoid SLBs (BTF of 2.73 ± 0.09 nN; Table 2). TRO caused the largest increase, followed by SQ and then ENT-03, with BTF values of 4.2 ± 0.2 , 3.5 ± 0.2 , and 3.0 ± 0.1 nN, respectively (Figure 6, Table 2).

All Three AMs Redistribute Cholesterol and GM1 Lipids in LUVs, with Efficacy TRO > SQ \cong ENT-03. Using lipid-lipid FRET, TRO was previously found to reorganize the spatial distribution of CHOL and GM1 molecules in LUVs, therein clustering CHOL molecules, separating CHOL from GM1 molecules, clustering GM1 molecules, and maintaining mutual distances of SM and DOPC from CHOL.¹¹ To investigate whether SQ and ENT-03 could have a similar impact, we carried out a series of lipid–lipid FRET experiments in the absence and presence of each AM. In these experiments, 0.0625% of a given lipid (relative to the total lipid content in LUVs) was labeled with a donor (D) fluorescent probe and the same fraction of CHOL was labeled with an acceptor (A) fluorescent probe, namely, BODIPY FL and BODIPY 542/563, respectively. Four different combinations of FRET pairs (GM1-D/CHOL-A, CHOL-D/CHOL-A, SM-D/CHOL-A, and DOPC-D/CHOL-A) were then analyzed in the presence of SQ and ENT-03 and then compared to data obtained with LUVs without AMs and with LUVs with TRO (Figure 7A–D). Both SQ and ENT-03 induced a similar and significant increment of FRET efficiency (E) in the CHOL-D/CHOL-A pair ($p < 0.001$) and a reduction in the GM1-D/CHOL-A pair ($p < 0.01$), indicating a reduction of the mean shortest distance between CHOL molecules or GM1 molecules and an increase of the distance between CHOL and GM1 molecules (Figure 7E,F, Table 2). This behavior was similar to that induced by TRO ($p < 0.001$ relative to absence of AM), but was found to occur to a significantly lesser extent (Figure 7E,F, Table 2). Neither SQ nor ENT-03 showed variations in the FRET E for the SM-D/CHOL-A and DOPC-D/CHOL-A pairs ($p > 0.05$), in agreement with the effect of TRO (Figure 7E,F, Table 2).

All Three AMs Displace α -Synuclein from DMPS LUVs, with Efficacy TRO \cong ENT-03 > SQ. Previous works showed that TRO and SQ were able to displace α -synuclein (α S) from small unilamellar vesicles (SUVs) composed of DMPS,^{4,5} and that this displacement could be monitored as a change from a LUV-bound α S conformation enriched with an α -helical structure and free, unbound, substantially disordered α S conformational state.^{4,5} We repeated the experiments with TRO and SQ and also extended the analysis to ENT-03, using DMPS LUVs rather than our ordinary LUVs to replicate the previously established protocol^{4,5} and because the strength of the binding of α S to lipids is strongly influenced by the chemical properties of the lipids.^{23–25} To this aim, $5 \mu\text{M}$ α S was incubated with 0.2 mg/mL DMPS LUVs for 30 min and then with increasing AM concentrations for 15 additional min.

All AMs were found to displace α S from LUVs in a dose-dependent manner, as shown by the progressive apparent two-state change from a typical α -helical CD spectrum, with negative peaks at 222 and 208 nm and a positive peak at 192 nm, to a typical random-coil spectrum, with a single negative peak at 198 nm (Figure 8A–C).

This conformational change was compared for the three AMs as a progressive increase of mean residue ellipticity at 222 nm, showing that SQ is slightly less effective, as it requires higher concentrations to displace the protein from the membrane relative to TRO and ENT-03, which had similar displacement activities (Figure 8D). This ranking suggests that the AM-induced displacement of α S from DMPS LUVs is mainly driven by electrostatic effects, given that TRO and ENT-03 are more positively charged than SQ at physiological pH.

All Three AMs Protect the Plasma Membrane of Cultured Cells from A β Oligomers, with Efficacy TRO > ENT-03 > SQ. We then passed from LUVs to cultured cells (human neuroblastoma SH-SY5Y cells) to investigate whether all three AMs bind to the plasma membrane of cells and protect them from misfolded protein oligomers. All three AMs were labeled with BODIPY TMR, which is a neutral and hydrophobic probe that does not alter the positive net charge of the AM. SH-SY5Y cells were treated with $5 \mu\text{M}$ TRO-BODIPY, SQ-BODIPY, or ENT-03-BODIPY for 30 min at room temperature and analyzed with confocal scanning microscopy (Figure 9A). All three AMs prominently bind to the plasma membrane, in accordance to the results obtained with LUVs. Moreover, cells treated with L-Arg-BODIPY, used here as a negative control, show the total absence of BODIPY-derived fluorescence (Figure 9A), confirming that the binding observed using AM-BODIPY is fully attributable to the AM, rather than the hydrophobic probe.

The protective effect of the three AMs against the ability of misfolded protein oligomers to cause cell dysfunction was evaluated using amyloid- β -derived diffusible ligands (ADDLs) composed of A β ₄₂ as sample oligomers and evaluating the influx of calcium ions (Ca^{2+}) from the extracellular space to the cytosol of cultured SH-SY5Y cells, which is thought to be the earliest insult following the oligomer-membrane interaction.^{26–30} SH-SY5Y cells were treated for 15 min with ADDLs ($1 \mu\text{M}$, monomer equivalents) in the absence or presence of different concentrations of AMs and then their Ca^{2+} levels were evaluated with a specific fluorescent probe that enters inside the cells and produces green fluorescence (F) only when bound to Ca^{2+} (Figure 9B,C). ADDLs caused a $660 \pm 30\%$ increase of Ca^{2+} relative to untreated cells, indicating a markedly heightened state of toxicity. Coincubation of the ADDLs with AMs caused a decrease of Ca^{2+} levels with a clear dose-dependence and AM-type dependence. In particular,




Figure 6. The three AMs increase the mechanical resistance of lipid bilayers to indentation or BTF. Breakthrough force (BTF) distributions measured on SLBs formed from LUVs prepared in the absence (A, gray) and in the presence of 5 μM TRO (B, blue), SQ (C, red), and ENT-03 (D, green). Distributions were obtained from at least six independent force maps. The statistically significant difference between AMs was calculated using a Kruskal-Wallis test, which resulted in $p < 0.001$, and a Dunn test, which highlighted a difference between each group with $p < 0.05$.

TRO was found to be more effective than ENT-03 at corresponding concentrations, and the difference was statistically significant when all doses were analyzed together ($p < 0.01$). TRO and ENT-03 were both more effective than SQ ($p < 0.001$ in both cases). At the highest AM concentration tested (5 μM), all three AMs were able to completely suppress the ADDL-induced Ca^{2+} influx down to the levels of untreated cells (Figure 9C).

Global Fitting Analysis Determines Quantitatively the Chemical Factors of AMs and the Physico-Chemical Determinants of Membrane Involved in the AM-Induced Membrane Protection in this Experimental Setting. All data of Ca^{2+} -derived fluorescence (F) shown in Figure 9C were converted into normalized response (R) values ranging from 0% (no effect) to 100% (full effect) using:

$$R = 100 \cdot \frac{(F_0 - F)}{(F_0 - F_{\text{untreated}})} \quad (1)$$

where F_0 and $F_{\text{untreated}}$ are the F values with and without ADDLs, respectively, both without AMs (corresponding to 659 ± 30 and $100 \pm 15\%$, respectively). The obtained R values were plotted versus AM concentration in one single semi-log plot to obtain the typical dose–response curve used in pharmacology (Figure 9D). The resulting plot was then fitted to the Hill equation, typically used to analyze dose–response curves and found to satisfactorily fit most dose–response curves:³¹

$$R = \frac{100}{1 + \left(\frac{\text{EC}_{50}}{[\text{AM}]}\right)^n} \quad (2)$$

where $[\text{AM}]$ is the AM molar concentration, EC_{50} is the molar AM concentration at which R was 50%, and n is the Hill coefficient. EC_{50} and n were parameters free to float in the fitting procedure, and values of $1.62 \pm 0.25 \times 10^{-7}$ M and 0.78 ± 0.09 were obtained, respectively (Figure 9D, $r = 0.9291$, $\text{RMSD} = 8.17\%$). A fairly good agreement was found between theoretical R values redetermined with eq 2 for all three AMs and corresponding experimental R values (Figure 9E, $r = 0.9291$, $\text{RMSD} = 8.17\%$). Nevertheless, the agreement was not entirely satisfactory due to differences among the three AMs.

To improve the agreement and identify the AM-induced membrane alterations responsible for the observed changes of R values at corresponding AM concentrations, we recognize two different contributions to the EC_{50} of the AMs: the change in charge and the change in packing, which add to an offset EC'_{50} value in the absence of these two changes (EC'_{50}):

$$\text{EC}_{50} = \text{EC}'_{50} + k_{\text{charge}} \cdot \Delta\zeta + k_{\text{packing}} \cdot \Delta p \quad (3)$$

The two contributions were considered additive, in the absence of knowledge of a well-defined relationship, as generally done in empirical equations.³² This leads to a phenomenological Hill equation, where all R values were analyzed in a multivariable and multiparameter global fitting procedure:

$$R = \frac{100}{1 + \left\{ \frac{(\text{EC}'_{50} + k_{\text{charge}} \cdot \Delta\zeta + k_{\text{packing}} \cdot \Delta p)}{[\text{AM}]} \right\}^n} \quad (4)$$

where $\Delta\zeta$ is the experimentally determined and normalized change of ζ observed upon AM addition (corresponding to the percent values reported in Table 2); Δp is the experimentally determined and normalized change of lipid distribution and packing observed upon AM addition (corresponding to the averaged three remaining percent values reported in Table 2); k_{charge} and k_{packing} are the proportionality constants for $\Delta\zeta$ and Δp , respectively; EC'_{50} is a parameter corresponding to EC_{50} when $\Delta\zeta$ and Δp are both equal to 0 and corresponds to the EC_{50} for a hypothetical nonnatural AM that does not affect ζ and p ; and n has the same meaning described for eq 2.




Figure 7. The three AMs redistribute CHOL and GM1 molecules in LUVs. (A–D) Fluorescence spectra of LUVs containing the indicated D-labeled lipid (green), A-labeled CHOL (orange), and both (blue) in the absence (A) and in the presence of TRO (B), SQ (C), and ENT-03 (D). (E) FRET efficiency (E) values obtained for the various pairs using eq 12 in the absence (gray) and presence of TRO (blue), SQ (red), and ENT-03 (green). Experimental errors are SEM ($n = 5$). The symbols *** refer to p values of <0.001 relative to r values obtained in the absence of AMs. (F) Mean shortest distances (r) between the indicated lipid-D and CHOL-A in absence and presence of AMs obtained from FRET E values reported in panel E using eq 13.

This equation represents a Hill equation integrated with the $k_{\text{charge}} \cdot \Delta\zeta$ and $k_{\text{packing}} \cdot \Delta p$ factors. Its three independent variables ($[AM]$, $\Delta\zeta$, and Δp) are used to express one dependent variable (R), upon the global fitting of the four constants (EC'_{50} , k_{charge} , k_{packing} , and n) using all the available data. Fitting all R values to eq 4 yielded values of $5.94 \pm 0.59 \times 10^{-7}$ M, $-3.99 \pm 0.82 \times 10^{-7}$, $-1.03 \pm 0.22 \times 10^{-7}$, and 0.795 \pm 0.015 for EC'_{50} , k_{charge} , k_{packing} , and n , respectively. The

equation can describe well the behavior of the three AMs plotted separately in three independent graphs (Figure 9F–H), where the three solid lines through the data do not represent the results of three independent fitting procedures, but are rather the result of one equation determined from the global fitting. A very good and improved agreement was found between theoretical R values redetermined with eq 4 for all




Figure 8. Far UV CD analysis of α -synuclein displacement exerted by the three AMs. (A–C) Far-UV CD spectra of α S in the absence and presence of DMPS LUVs incubated with increasing concentrations of TRO (A), SQ (B), and ENT-03 (C). Spectra were blank subtracted and normalized using eq 14. (D, E) Mean residue ellipticity at 222 nm (D) and 192 nm (E) of α S incubated with DMPS LUVs and increasing concentrations of TRO (blue), SQ (red), and ENT-03 (green).

three AMs and the corresponding experimental R values (Figure 9I, $r = 0.9890$, RMSD = 4.49%).

The model and resulting eq 4 were validated using the leave-one-out cross-validation (LOOCV) method, in which each experimental R value was left out from the analysis, one by one, to redetermine, through the global fitting, the four constants of eq 4 and the resulting theoretical R value corresponding to the left-out experimental R value. A good agreement was found between redetermined theoretical versus experimental R values (Figure S4, $r = 0.982$, RMSD = 5.70%), indicating the ability of eq 4 to predict new R values that are not present in the analysis.

What can we learn from this analysis? The k_{charge} and k_{packing} values are both negative, indicating that both the partial charge neutralization and compaction of the membrane contribute to the increase of AM potency (corresponding to a decreased EC_{50} value). Their relative contributions amount to 79 ± 7 and $21 \pm 7\%$, respectively, indicating that the charge effect is predominant. A hypothetical nonnatural AM that does not affect ζ and p (for example, having a monoamine group and shorter tail on the other side) would have a potency 6–7-fold lower than that of TRO. TRO appears the most effective AM because it produces the highest effects in terms of both membrane neutralization and compaction. ENT-03 is marginally, albeit significantly, less effective because it has a much lower effect on membrane compaction. This feature accounts for only $21 \pm 7\%$ of the effect, therein explaining why its potency is only slightly lower. By contrast, SQ appears markedly less effective because it leads to a much lower change in charge than TRO and ENT-03, despite a packing effect similar to that of ENT-03.

We also included the different binding affinities (K_D) of the AMs for LUVs as a parameter in the global fitting, but this has not resulted in any improvement, particularly because the least protective SQ has also the highest binding affinity for the lipid bilayer, suggesting that binding affinity is a less relevant factor. This can be rationalized by the fact that the lipid concentration is very high in the two-dimensional carpets of cells, making the AMs work in a saturation regime similar to that of high LUV concentration in the conditions explored in Figure 3. On different grounds, AM occupancy on the membrane is also not a factor because all AM concentrations tested here on cells (0–5 μM) are well below the AM concentrations determined experimentally at saturation on LUVs (12–50 μM), and the latter are certainly even higher in cell cultures.

Potency and Membrane Perturbations Can Be Attributed to Specific AM Chemical Groups. To attribute the potency as well as the k_{charge} and k_{packing} parameters and their numerical values to discrete chemical groups within the AMs, we repeated the analysis using modifiers of the Hill equation that account for chemical differences between the three AMs ($a_{\text{polyamine}}$ and $a_{\text{SO}_3/\text{COO}}$) rather than experimental observables ($\Delta\zeta$ and Δp):

$$R = \frac{100}{1 + \left\{ \frac{(EC'_{50} + a_{\text{polyamine}} + a_{\text{SO}_3/\text{COO}})}{[\text{AM}]} \right\}^n} \quad (5)$$

where $[\text{AM}]$ and R are the independent and dependent variables, respectively; EC'_{50} , $a_{\text{polyamine}}$, and $a_{\text{SO}_3/\text{COO}}$ are constants free to float in the global fitting analysis using all the available data. $a_{\text{polyamine}}$ and $a_{\text{SO}_3/\text{COO}}$ are parameters accounting for the change of the EC'_{50} parameter when a spermine, rather than a spermidine, and a $-\text{SO}_3^-$, rather than a




Figure 9. The three AMs bind to the plasma membrane of SH-SY5Y cells and prevent the increase of intracellular Ca^{2+} levels induced by ADDLs (global fitting analysis). (A) Representative confocal microscopy images (median planes parallel to the coverslip) of SH-SY5Y cells incubated for 30 min at room temperature with $5 \mu\text{M}$ of L-Arg-BODIPY, TRO-BODIPY, SQ-BODIPY, or ENT-03-BODIPY (probe:molecule of 1:10). Blue and red fluorescences indicate Hoechst-labeled nuclei and AM-BODIPY, respectively. (B) Representative confocal scanning microscopy images of free Ca^{2+} levels in untreated SH-SY5Y cells or in cells treated for 15 min with $1 \mu\text{M}$ ADDLs in the absence or presence of $1 \mu\text{M}$ AMs. (C) Intracellular free Ca^{2+} -derived fluorescence in untreated SH-SY5Y cells or in cells treated for 15 min with ADDLs in the absence or presence of the indicated concentrations of AMs. Experimental errors are SEM ($n = 4$). *** symbols refer to p values < 0.001 relative to untreated cells. §§ and §§§ symbols refer to p values < 0.01 and < 0.001 , respectively, relative to ADDLs without AMs. (D) Normalized dose–response curve obtained from Ca^{2+} -derived fluorescence data of all AMs in panel C and fitted to eq 2. (E) Plot reporting theoretical versus experimental response values obtained from eq 2. (F–H) Normalized dose–response curves for TRO (blue), SQ (red), and ENT-03 (green) obtained from Ca^{2+} -derived fluorescence data in panel C. In each plot, the lines through the data do not represent independent fitting procedures using eq 2, but result from global fitting using only eq 4, in all cases with corresponding values of ζ potential, BTF, and FRET data. Experimental errors are SEM ($n = 4$). (I) Plot reporting theoretical versus experimental response values obtained from eq 4.

– COO^- group, are present in the AM, respectively. The two parameters were constrained to 0 when the spermine and $-\text{SO}_3^-$ groups were absent and replaced by spermidine and carboxylate, respectively. Fitting all R values to eq 5 yielded values of $3.83 \pm 0.39 \times 10^{-7}$, $-2.36 \pm 0.47 \times 10^{-7}$, and $-0.55 \pm 0.12 \times 10^{-7}$ M for EC'_{50} , $a_{\text{polyamine}}$, and $a_{\text{SO}_3/\text{COO}}$, respectively ($r = 0.9820$, RMSD = 4.50%).

The $a_{\text{polyamine}}$ and $a_{\text{SO}_3/\text{COO}}$ values were again found to be negative, indicating that the longer spermine and SO_3^- -containing tail cause a potency increase (or EC_{50} decrease)

relative to a hypothetical nonnatural AM having a spermidine and carboxylate group. They account for 81 ± 7 and $19 \pm 7\%$ of the effect, respectively, in good agreement with the values obtained with the experimental analysis and confirming that the charge effect of the polyamine is predominant over the chemistry of the tail on the other side of the molecule that causes a redistribution of lipids and increased packing. The net positive charge of AMs allows a larger decrease of the negative charge of the cell membrane provided by GM1, which is a physicochemical change reported to be crucial in protecting




Figure 10. Contributions of the various membrane alterations and chemical groups of AMs to their potency in this experimental setting. (A) Contributions of the various types of membrane alterations and (B) of the chemical groups of AMs to the EC_{50} parameter in this experimental setting. The numbers reported in panel B refer to the contributions to the AM potency in membrane protection of SH-SY5Y cultured cells against misfolded protein oligomers of $A\beta$ (ADDLs, 1 μM monomer equivalents) causing Ca^{2+} influx. The chemical formula in the image refers to TRO. (C) Representative AMs with their potencies (EC_{50} values) predicted in our experimental setting using the values reported in panel B. The EC_{50} values predicted for TRO, SQ, and ENT-03 are in good agreement with those observed experimentally.

biological membranes from $A\beta$ oligomer binding and resulting cell toxicity also using other compounds, such as europium positive ions.³³ The EC'_{50} value obtained for the hypothetical nonnatural AM with spermidine and carboxylate ($3.83 \pm 0.39 \times 10^{-7}$ M), which is higher than that of any AM analyzed here having at least the spermine (triamine) or SO_3^- group, is lower than the hypothetical nonnatural AM of the previous analysis having a monoamine group and shorter tail on the other side ($5.94 \pm 0.59 \times 10^{-7}$ M). Since all natural and nonnatural AMs studied here have a steroid scaffold, their EC_{50} values remain in the 10^{-8} – 10^{-7} M range.

CONCLUSIONS

The three natural AMs studied here have a different chemistry and combination of specific, relevant functional groups. Consequently, their binding to the lipid bilayer of a liposome membrane results in different perturbations of the physico-

chemical properties of the liposome bilayer, such as their surface charge (ζ), resistance to a mechanical breakthrough force (BTF) perpendicular to its plane and distribution of CHOL, and GM1 lipids (r). Importantly, their binding to the membranes of cultured SH-SY5Y cells results into different degrees of protection against the action of misfolded protein oligomers of the $A\beta_{42}$ peptide to Ca^{2+} influx. The protection depends on AM concentration, level of charge neutralization of the membrane and change of packing resulting from lipid redistribution.

Using a global fitting analysis, we described quantitatively the level of AM-mediated protection of the cell membrane as a function of all these factors, which allows the quantification of the weights that the different types of membrane alterations have in this protection (eq 4) and the contributions of the various chemical groups of AMs in their protective mechanism against oligomers (eq 5). In particular, the results of the global

fitting analysis presented in the previous two sections allow us to calculate the contributions of the various types of membrane alterations (Figure 10A) and chemical groups of AMs (Figure 10B) to the EC₅₀ parameter in the experimental setting described here based on cultured SH-SY5Y cells and Ca²⁺ influx measurements as a readout of membrane destabilization. They also provide hints to anticipate the effects, in a similar experimental setting, of other AMs isolated from sharks,¹⁸ AMs present in other animals that will probably be discovered in the next few years, monoamino-steroid molecules present in plants,^{34–36} and synthetic AMs (Figure 10C). Hence, these results help establish molecular principles for the further study and rational optimization of aminosterols and, more generally, help elucidate the means by which the physico-chemical properties of cell membranes can be targeted pharmacologically.

EXPERIMENTAL SECTION

Preparation of Large Unilamellar Vesicles (LUVs). Liposomes were produced with a lipid mixture composed of 1,2-dioleoyl-sn-glycero-3-phosphocoline (DOPC, Avanti Polar Lipids) and sphingomyelin (SM, Sigma-Aldrich) in a molar ratio of 2:1 (mol/mol), 1% (mol) cholesterol (CHOL, Sigma-Aldrich), and 1% (mol) monosialotetrahexosylganglioside 1 (GM1, Avanti Polar Lipids). The lipids were dissolved in chloroform/methanol (2:1), and the organic solvent was removed by evaporation *in vacuo* (Univapo 150H, UniEquip) for 180 min. The mixture was hydrated at a total lipid concentration of 1.0 mg/mL with distilled water to form multilamellar vesicles (MLVs), left to swell for 1 h at 60 °C, and then extruded 17 times through a polycarbonate membrane with 100 nm pores using a miniextruder (Avanti Polar Lipids) at the same temperature, to form large unilamellar vesicles (LUVs). After cooling to room temperature, LUVs were stored at 4 °C for a maximum of 1 week. For the measurement of the ζ potential and BTF, and for the lipid-lipid FRET experiments, 5 μ M of each AM was added during the hydration phase of LUVs preparation.

Labeling of Aminosterols with BODIPY TMR and Alexa Fluor 594. SQ and TRO were synthesized by coupling spermidine and spermine, respectively, to the (5 α ,7 α ,24R)-3-keto-7-hydroxycholestan-24-ol sulfate steroid intermediate as previously described.^{37–39} The synthesis of ENT-03 was carried out similarly to the other AMs, by coupling a polyamine tail to a steroidal skeleton;¹⁶ the step by step procedure is reported in a deposited patent and will be published in a separate paper (Patent CN114929724; 2022). The >95% chemical purities of all AMs were assessed by HPLC-ELSD (Figures S5–S7) and ¹H-NMR (Figures S8–S10). All AMs were stored as powders until use. For the labeling procedure, AMs were dissolved in distilled water to obtain a 100 mM stock solution and stored at 4 °C. BODIPY TMR-X NHS Ester and Alexa Fluor 594 NHS Ester (BODIPY and A594, respectively, ThermoFisher Scientific) were both dissolved in anhydrous DMSO to obtain 15 and 10 mM stock solutions, respectively, and stored at –20 °C. For labeling, 5 mM AM, 0.5 mM dye, 0.1 M sodium bicarbonate buffer, pH 8.3 for BODIPY and pH 7.0 for A594, were incubated in a final volume of 20 μ L at 25 °C for 2 h under mild orbital shaking. During labeling with BODIPY the AM precipitates, therefore, after the incubation, the solution was centrifuged at 18,000g for 15 min; the pellet was dried with a nitrogen flow and resuspended in 20 μ L DMSO to maintain the initial concentrations. During labeling with A594, TRO remains in solution, whereas SQ and ENT-03 precipitate. Hence, the solution with TRO labeled with A594 was directly used after incubation, while those with SQ and ENT-03 were centrifuged and resuspended in DMSO as described for the BODIPY labeling. With these procedures, the labeled:total AM was 1:10 in all cases. No unreacted dye was detected using mass spectrometry, following a previously described procedure.¹¹ As a negative control, L-Arg was labeled with both BODIPY and A594 under the same conditions used for AM labeling and no precipitate was observed.

Fluorescence Anisotropy of Fluorescently Labeled Aminosterols. BODIPY or A594-labeled AMs and L-Arg (negative control) were diluted with distilled water to 10 μ M. The fluorescence anisotropy (r) values were then acquired at 570 nm after excitation at 544 nm and at 617 nm after excitation at 590 nm, respectively, in the absence and presence of 0.5 mg/mL unlabeled LUVs incubated for 15 min in the dark, using a 3 × 3 mm black walls quartz cell at 25 °C on an Agilent Cary Eclipse spectrofluorometer (Agilent Technologies) equipped with a thermostatted cell holder attached to an Agilent PCB 1500 water Peltier system.

Fluorescence Emission of Fluorescently Labeled Aminosterols. BODIPY or A594-labeled AMs and L-Arg (negative control) were diluted with distilled water to 10 μ M. Fluorescence emission spectra of AMs and L-Arg labeled with BODIPY and A594 were acquired from 550 to 650 nm (excitation at 544 nm) and from 600 to 700 nm (excitation at 590 nm), respectively, in the absence and presence of 0.5 mg/mL unlabeled LUVs incubated for 15 min in the dark, using the cell and spectrofluorometer described above.

Binding Assay of Fluorescently Labeled Aminosterols and LUVs. BODIPY or A594-labeled AMs and L-Arg (negative control) were diluted with distilled water to 10 μ M and incubated with increasing concentrations of unlabeled LUVs (from 0.0 to 1.0 mg/mL) for 15 min at 25 °C in the dark. Fluorescence emission of BODIPY and A594-labeled AMs and L-Arg were then acquired at 572 nm (excitation at 535 nm), and at 612 nm (excitation at 590 nm), respectively, using the cell and spectrofluorometer described above. The weak fluorescence contribution of unlabeled LUVs was subtracted from fluorescence emission spectra, and resulting values were then normalized to the value obtained in the absence of LUVs (taken as 100%). The fluorescence emission intensity was then plotted versus LUV concentration, and data points were then fitted with:

$$F = F_0 - A \cdot \frac{[\text{LUVs}]}{K_D + [\text{LUVs}]} \quad (6)$$

where F is the fluorescence intensity at a given LUV concentration, F_0 is fluorescence intensity at 0.0 mg/mL LUVs, A is the difference between the fluorescence emission of unbound and bound AMs, and K_D is the dissociation constant of the LUV-AM complex.

Stopped-Flow Kinetic Analysis of TRO-LUV Binding. TRO-A594 (50 μ M) was diluted 5-fold into solutions containing different concentrations of LUVs dissolved in H₂O. We used a Bio-logic SFM-3 stopped-flow device (Claix, France) attached to a fluorescence detection system, an FC-08 cuvette (path length 0.08 cm), an excitation at 380 nm, and a band pass filter to collect emission above 475 nm. The flow rate was 2.19 mL/s. The injection time, total volume, and dead-time were 160 ms, 350 μ L, and 14 ms, respectively. The final conditions after dilution were 10 μ M TRO-A594, with LUV concentrations ranging from 0.12 to 1.00 mg/mL, 25 °C. Each trace was averaged over 2–7 experiments, normalized to the maximum fluorescence, and then analyzed with a double exponential equation:

$$f(t) = m \cdot t + q + A_1 \cdot e^{-k_1 t} + A_2 \cdot e^{-k_2 t} \quad (7)$$

where $f(t)$ is the fluorescence recorded at time t , m and q are the slope and intercept of the plateau signal, respectively, A_1 and A_2 are the amplitudes of the exponential phases, and k_1 and k_2 are their apparent rate constants. Plots of k_1 and k_2 versus LUV concentration were fitted to straight lines:⁴⁰

$$k_1 = k_{\text{on}(1)} \cdot [\text{LUVs}] + k_{\text{off}(1)} \quad (8)$$

$$k_2 = k_{\text{on}(2)} \cdot [\text{LUVs}] + k_{\text{off}(2)} \quad (9)$$

Light Scattering Analysis of LUVs in the Presence of Saturating Concentrations of Aminosterols. LUVs were diluted with distilled water to 0.5 mg/mL and incubated for 15 min at 25 °C with increasing concentrations of AMs (from 0 to 100 μ M). The size distributions (light scattering versus apparent hydrodynamic diameter) and count rate (kilocounts per second, kcps) were then recorded at 25 °C, using a Zetasizer Nano S or APS (Malvern), thermostatted

with a Peltier temperature controller, measurement position 4.20 mm, attenuator 6, and using disposable low volume (45 μL) plastic cuvettes. According to the laws of light scattering, the following equation holds:

$$I = n \cdot m^2 \cdot I_0 \quad (10)$$

where I is the total intensity of light scattered by LUVs in kcps, n is the number of LUVs, m is the mass of a single LUV, and I_0 is the intensity of light scattered by a single unitary mass of LUV in kcps. LUV hydrodynamic diameter did not change with addition of any of the AMs, indicating that n and I_0 remain constant. By contrast, when the AM is incorporated into the LUVs, m increases. The relative increase of LUV mass determined by the addition of AMs was then calculated with:

$$\frac{m_{\text{AM}}}{m_{\text{NO}}} = \sqrt{\frac{I_{\text{AM}}}{I_{\text{NO}}}} \quad (11)$$

where I_{AM} and I_{NO} are the intensities of light scattered by LUVs in the presence and absence of a given concentration of AM and m_{AM} and m_{NO} are the LUV mass concentrations in the presence and absence of a given concentration of AM. The obtained data were then plotted versus AM concentration.

Microfluidics of TRO in the Presence of LUVs. LUVs were diluted with distilled water to 0.5 mg/mL and incubated for 15 min at 25 °C with 10–100 μM TRO-A594 or 20 μM TRO-BODIPY (1:10 dye:TRO) or 2 μM CHOL-BODIPY (1:1 dye:CHOL); samples with 10 or 50 μM TRO-A594 without LUVs were also prepared. The diffusion of the fluorescently labeled molecule in the various samples was evaluated with the microfluidic technique using a Fluidity One-W instrument (Fluidic Analytics) and placing a 5 μL drop of the sample on a disposable microfluidic chip made of cyclic olefin copolymer (COC) manufactured using injection molding (Fluidic Analytics). The diffusion was evaluated as the ratio of fluorescence values in the diffused versus that in the undiffused channels (F_d/F_{und}) or as the ratio of fluorescence values in the diffused channel versus total fluorescence [$F_d/(F_d + F_{\text{und}})$]. This ratio parameter correlated directly with diffusion rapidity and inversely with size of the fluorescent molecule or its complex with LUVs. When this value was in the appropriate range, it was converted automatically by the instrument into a hydrodynamic radius (R_h).

ζ Potential Measurements. Zeta potential (ζ) measurements were performed with a Zetasizer Pro Red Label (Malvern). LUVs were covesiculated with 5 μM of each AM at a total lipid concentration of 1 mg/mL. About 600 μL of each LUV sample was diluted to obtain a total lipid concentration of 0.25 mg/mL, with phosphate buffer, 5.57 mM ionic strength, pH 7, 20 °C, and put in a disposable folded capillary cell (polycarbonate, Malvern). Each ζ potential value is the average of three independent runs; for each temperature, the ζ potential was determined as the mean of 5–8 measurements. The reported error is the standard deviation of the measurements. The measurements were performed in the range 10–60 °C, every 2 °C (except every 1 °C in the range 38–50 °C for ENT-03 containing LUVs, to better appreciate the transition). The electrophoretic mobility measurements were converted into ζ values according to the Smoluchowsky model.⁴¹ The temperature was internally controlled (accuracy ± 0.1 °C). The ζ potential measurements were also used to determine the transition temperature (T_m) in LUV systems.⁴² The T_m values were determined by analyzing the first-order derivative of ζ with respect to temperature ($d\zeta/dT$) as a function of temperature: the T_m corresponds to the minimum of the curve, while the amplitude of the transition was assumed to correspond to the full width at half maximum (FWHM) of the derivative curves.

Atomic Force Microscopy (AFM). LUVs were prepared at a total lipid concentration of 1.0 mg/mL covesiculated with 5 μM of each AM. Supported lipid bilayers (SLBs) were obtained by depositing 40 μL of each LUV suspension (after a ten-fold dilution) and 10 μL of a 10 mM CaCl_2 solution onto a $1.0 \times 1.0 \text{ cm}^2$ freshly cleaved mica substrate. The samples were stored for 10 min at room temperature

and then incubated for 15 min at 60 °C in a closed chamber at 100% relative humidity. The samples were cooled down at room temperature for 2 h and finally gently rinsed with Milli-Q water to remove nondeposited vesicles. Prior to AFM imaging, samples were kept again at room temperature in a closed chamber at 100% relative humidity. AFM imaging usually started 1.5 h after rinsing.

Force spectroscopy measurements were performed under a liquid environment with a Multimode SPM (Bruker) equipped with “E” scanning head (maximum scan size 15 μm) and driven by a Nanoscope V controller (Bruker). Triangular silicon nitride cantilevers (DNP-10, Bruker, nominal spring constant 0.24 N/m) were used. The actual spring constant of each cantilever was determined *in situ* using the thermal noise method.⁴³ Force maps consisting of 128×128 force distance curves were acquired point-by-point on scan areas of $5 \times 5 \mu\text{m}^2$ or $2.5 \times 2.5 \mu\text{m}^2$. The maximum force load was 15–18 nN. Breakthrough forces were evaluated from the force–distance curves data sets using a home-built software.

Lipid–Lipid FRET. LUVs were prepared at a total lipid concentration of 1.0 mg/mL, as described above. TRO, SQ, and ENT-03, when present, were added during the hydration phase to a final concentration of 5 μM . BODIPY-FL C5-ganglioside GM1 (GM1-D), BODIPY-FL-cholesterol (CHOL-D), BODIPY-FL-sphingomyelin (SM-D, commercial name TopFluor Sphingomyelin, Avanti Polar Lipids), and BODIPY-FL-DOPC (DOPC-D, commercial name TopFluor PC, Avanti Polar Lipids) were used as donor lipids. Cholesteryl 4,4-difluoro-5-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene-3-undecanoate (CHOL-A, commercial name CholEsteryl BODIPY 542/563 C11, ThermoFisher Scientific) was used as an acceptor lipid. The molar fraction of each lipid labeled with D or with A was 0.0625% of total lipids in all cases.

Fluorescence spectra of LUVs containing only lipid-D, only CHOL-A, and both lipid-D and CHOL-A were acquired using the cell and spectrofluorometer described above, at 25 °C, with excitation at 450 nm and emission from 480 to 640 nm. FRET efficiencies (E) were calculated as

$$E = 1 - \left(\frac{F_{\text{DA}}}{F_{\text{D}}} \right) \quad (12)$$

where F_{DA} is the fluorescence intensity of D in the presence of A, and F_{D} is the fluorescence intensity of D in the absence of A.⁴⁴ FRET E calculated with eq 12 was converted into distance between D and A (r) using:⁴⁴

$$r = \sqrt[6]{\frac{R_0^6 - E \cdot R_0^6}{E}} \quad (13)$$

where R_0 is the Forster distance and was previously calculated for this D/A probe pair.¹¹

FAR-UV CD Spectroscopy. αS (5 μM) was incubated with DMPS LUVs (250 μM total lipids, corresponding to 0.2 mg/mL total lipids) for 30 min and then with increasing concentrations of TRO, SQ, or ENT-03 (0, 10, 20, 30, 40, 50, 60, and 70 μM) for 15 additional min, in 20 mM sodium phosphate buffer, pH 6.5, at 30 °C. LUVs were prepared with the same procedure reported above, but using 100% DMPS. Far-UV CD spectra were recorded on a Jasco J-810 spectropolarimeter equipped with a thermostated cell holder attached to a Thermo Haake C25P water bath using a quartz cuvette with path length of 1 mm, at 30 °C. CD spectra were recorded from 180 to 260 nm by averaging 5 spectra with a data pitch of 0.2 nm, a scanning speed of 50 nm/min, and a response time of 1 s. All spectra were blank subtracted and truncated at HT > 700 V, then normalized to mean molar residue ellipticity using:

$$[\theta] = \frac{\theta}{\left(\frac{10 \cdot N \cdot d \cdot c}{mw} \right)} \quad (14)$$

where $[\theta]$ is the mean residue ellipticity in $\text{deg cm}^2 \text{ dmol}^{-1}$, θ is the ellipticity in mdeg, N is the number of residues, d is the optical path in cm, c is the concentration in g/l, and mw is the molecular weight in g/

mol. For all analyses, $[\theta]$ at 222 and 192 nm was plotted as a function of AM concentration.

Preparation of $A\beta_{42}$ ADDLs. Lyophilized $A\beta_{42}$ (Bachem) was dissolved in HFIP to 1.0 mM and incubated for 1 h at room temperature to allow complete peptide monomerization. $A\beta_{42}$ -derived diffusible ligands (ADDLs) were prepared as described previously.⁴⁵ In particular, the HFIP was evaporated with a gentle flow of N_2 and the dried protein was resuspended to 5 mM with DMSO and then diluted with phenol red free F-12 HAM to 100 μ M. The sample was then incubated at 4 °C for 24 h and centrifuged at 12000g for 10 min, 4 °C, to collect the supernatant containing the oligomers.

Cell Culture. Authenticated human SH-SY5Y neuroblastoma cells were purchased from A.T.C.C. and cultured in Dulbecco's Modified Eagle's Medium (DMEM), F-12 Ham with 25 mM 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES), and $NaHCO_3$ (1:1) supplemented with 10% fetal bovine serum (FBS), 1 mM glutamine, and 1% penicillin and streptomycin solution (Sigma-Aldrich). Cells were maintained in a 5% CO_2 humidified atmosphere at 37 °C, grown until 80% confluence for a maximum of 20 passages, and routinely tested to ensure that they were free from mycoplasma contamination.⁴⁶ The cell line was authenticated by the European Collection of Authenticated Cell Cultures using short tandem repeat loci analyses.

Binding of Aminosterols to Cells. SH-SY5Y cells were plated in 12-well plates containing coverslips at a density of 50,000 cells per well. 24 h after plating, the cells were washed with phosphate-buffered saline (PBS) and incubated at room temperature for 30 min with 5 μ M TRO-BODIPY, SQ-BODIPY, ENT-03-BODIPY, or L-Arg-BODIPY (1:10 dye:molecule) diluted in the Leibovitz's L-15 (ThermoFisher Scientific), a medium designed for supporting cell growth in the absence of CO_2 equilibration. Ten min before the incubation ending, the Hoechst 33342 dye was added to the culture medium (10 μ g/mL). The analysis of AM-derived fluorescence and nuclei-derived fluorescence were performed on a Nikon Eclipse TE300 C2 confocal laser scanning microscope (Nikon) equipped with a Nikon 60x immersion oil objective (Apo Plan, NA 1.4) and with Coherent CUBE (diode 405 nm) and Coherent Sapphire (Sapphire 561 nm) lasers. The emission filters for imaging were 452/45 and 595/60 nm. All settings, including pinhole diameter, detector gain and laser power, were optimized for each analysis.

Measurement of Cytosolic Ca^{2+} Levels. SH-SY5Y cells were plated in 12-well plates containing coverslips at a density of 40,000 cells per well. 24 h after plating, the cells were washed with PBS and incubated at 37 °C for 15 min with ADDLs (1 μ M, monomer equivalents) in the absence or presence of increasing concentrations (0.05, 0.1, 0.5, 1, 2.5, and 5 μ M) of TRO, SQ, or ENT-03. Cytosolic Ca^{2+} levels were measured in living SH-SY5Y cells after the different treatments, by loading the cells with 4 μ M Fluo-4 AM (Thermo Fisher Scientific) for 10 min, as previously reported.⁴⁶ Ca^{2+} levels were detected after excitation at 488 nm and emission at 520–580 nm, by a TCS SP8 scanning confocal microscopy system (Leica Microsystems), equipped with an argon laser source. A series of 1 μ m thick optical sections (1024 \times 1024 pixels) were taken through the cell depth for each sample using a Leica Plan Apo 63x oil immersion objective, and all sections were projected as a single composite image by superimposition. The confocal microscope was set at optimal acquisition conditions, e.g., pinhole diameters, detector gain, and laser powers. Settings were maintained constant for each analysis. Images were then analyzed using the ImageJ (NIH) software (Rasband 1997–2018). Fluorescence intensities were typically expressed as a percentage of that measured in untreated cells.

■ ASSOCIATED CONTENT

SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c00182>.

Representative trace of stopped flow experiments, showing the fluorescence emitted during the binding of 10 μ M TRO-A594 with 0.20 mg/mL LUVs (Figure

S1); DLS size distributions of LUVs incubated with the three AMs (Figure S2); microfluidics of different concentrations of TRO-A594 in the absence or presence of LUVs (Figure S3); plot reporting theoretical versus experimental R values obtained using the leave-one-out cross-validation (LOOCV) method (Figure S4); chemical purity assessed by HPLC-ELSD of SQ, TRO, and ENT-03 (Figures S5–S7); chemical identity assessed by 1H -NMR of SQ, TRO, and ENT-03 (Figure S8–10); and chemical structures and molecular formula strings of SQ, TRO, and ENT-03 (Figure S11) (PDF)

TRO, SQ, and ENT-03 structures and corresponding formula strings (CSV)

■ AUTHOR INFORMATION

Corresponding Author

Fabrizio Chiti – Department of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence 50134, Italy; orcid.org/0000-0002-1330-1289; Email: fabrizio.chiti@unifi.it

Authors

Silvia Errico – Department of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence 50134, Italy; Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK; orcid.org/0000-0001-6197-9740

Giacomo Lucchesi – Department of Chemistry “Ugo Schiff” and CSGI, University of Florence, Sesto Fiorentino 50019, Italy

Davide Odino – Department of Physics, University of Genoa, Genoa 16146, Italy

Enass Youssef Osman – Department of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence 50134, Italy; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta 31527, The Arab Republic of Egypt

Roberta Cascella – Department of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence 50134, Italy; orcid.org/0000-0001-9856-6843

Lorenzo Neri – Department of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence 50134, Italy

Claudia Capitini – European Laboratory for Non-linear Spectroscopy (LENS), Sesto Fiorentino 50019, Italy; Department of Physics and Astronomy, University of Florence, Sesto Fiorentino 50019, Italy; National Institute of Optics, National Research Council of Italy (CNR), Florence 50125, Italy

Martino Calamai – European Laboratory for Non-linear Spectroscopy (LENS), Sesto Fiorentino 50019, Italy; National Institute of Optics, National Research Council of Italy (CNR), Florence 50125, Italy; orcid.org/0000-0002-4031-7235

Francesco Bemporad – Department of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence 50134, Italy

Cristina Cecchi – Department of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence 50134, Italy; orcid.org/0000-0001-8387-7737

William A. Kinney – Enterin Research Institute Inc., Philadelphia, Pennsylvania 19103, United States; orcid.org/0000-0001-7669-3817

Denise Barbut – Enterin Research Institute Inc., Philadelphia, Pennsylvania 19103, United States

Annalisa Relini – Department of Physics, University of Genoa, Genoa 16146, Italy; orcid.org/0000-0002-4040-9279

Claudio Canale – Department of Physics, University of Genoa, Genoa 16146, Italy

Gabriella Caminati – Department of Chemistry “Ugo Schiff” and CSGI, University of Florence, Sesto Fiorentino 50019, Italy; orcid.org/0000-0002-5947-7757

Ryan Limbocker – Department of Chemistry and Life Science, United States Military Academy, West Point, New York 10996, United States; orcid.org/0000-0002-6030-6656

Michele Vendruscolo – Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK; orcid.org/0000-0002-3616-1610

Michael Zasloff – Enterin Research Institute Inc., Philadelphia, Pennsylvania 19103, United States; MedStar Georgetown Transplant Institute, Georgetown University School of Medicine, Washington, District of Columbia 20007, United States

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acs.jmedchem.3c00182>

Author Contributions

Conceptualization: F.C.; formal analysis: S.E., G.L., D.O., E.Y.O., R.C., L.N., F.B., A.R., G.C., C.Capitini, M.C., C.Cecchi, and F.C.; funding acquisition: F.C., M.V., G.C., A.R., M.Z., and W.A.K.; investigation: S.E., G.L., D.O., E.Y.O., R.C., L.N., C.Capitini, and F.B.; methodology: F.C.; project administration: F.C.; resources: M.Z., W.A.K., and D.B.; supervision: F.C.; validation: S.E. and F.C.; visualization: S.E., F.C., L.N., G.L., and A.R.; writing—original draft: S.E. and F.C.; and writing—review and editing: S.E., F.C., M.V., R.L., R.C., C.Canale, D.B., F.B., A.R., G.C., C.Capitini, M.C., M.Z., and W.A.K.

Notes

The authors declare the following competing interest(s): M.Z. and D.B. are inventors in patents for the use of the three AMs in the treatment of Alzheimer’s and Parkinson’s diseases and are cofounders and stockholders in Enterin, Inc. M.V. is a founder of Wren Therapeutics Ltd., which is independently pursuing inhibitors of protein aggregation. The remaining authors declare no competing interests. The views expressed herein are those of the authors and do not reflect the position of the United States Military Academy, the Department of the Army, or the Department of Defense.

ACKNOWLEDGMENTS

This research was funded by the Regione Toscana (FAS-Salute 2017, project PRAMA); the University of Florence (Fondi di Ateneo). MIUR-Italy “Progetto Dipartimenti di Eccellenza 2018-2022” allocated to Department of Chemistry “Ugo Schiff” (Florence), Department of Experimental and Clinical Biomedical Sciences “Mario Serio” (Florence) and Department of Physics (Genoa). The project has received funding also from Horizon 2020 research and innovation programme, Integrated Initiative of European Laser Research Infrastructures – LASERLAB-EUROPE, Grant Agreement number

871124; and from the Italian Ministry for Education within the framework of the Euro-Bioimaging Italian Node (ESFRI research infrastructure). We thank Riccardo Ferrando for help in force map data elaboration. We thank Alfonso de Simone for providing α S.

ABBREVIATIONS USED

A, acceptor; A594, Alexa Fluor 594 NHS Ester; AFM, atomic force microscopy; AM-A594, Alexa Fluor 594-labeled AM; AM-BODIPY, BODIPY TMR-X-labeled AM; AMs, amino-sterols; BODIPY, BODIPY TMR-X NHS Ester; BTF, breakthrough force; CHOL, cholesterol; CHOL-A, Cholesteryl 4,4-difluoro-5-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene-3-undecanoate; CHOL-D, BODIPY-FL-cholesterol; COC, cyclic olefin copolymer; D, donor; DMEM, Dulbecco’s Modified Eagle’s Medium; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocoline; DOPC-D, BODIPY-FL-DOPC; FBS, fetal bovine serum; F, fluorescence; FTD, frontotemporal dementia; GM1, monosialotetrahexosylganglioside 1; GM1-D, BODIPY-FL C5-ganglioside GM1; HEPES, 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid; LOOCV, leave-one-out cross-validation; LUVs, large unilamellar vesicles; MLVs, multilamellar vesicles; PrP^{sc}, prion protein; R, normalized response; R_h , hydrodynamic radius; SE, spongiform encephalopathies; SLBs, supported lipid bilayers; SM-D, BODIPY-FL-sphingomyelin; SQ, squalamine; SUVs, small unilamellar vesicles; T_m , transition temperature; TRO, trodusquemine; α S, α -synuclein; ζ , zeta potential

REFERENCES

- (1) Chiti, F.; Dobson, C. M. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. *Annu. Rev. Biochem.* **2017**, *86*, 27–68.
- (2) Dugger, B. N.; Dickson, D. W. Pathology of Neurodegenerative Diseases. *Cold Spring Harbor Perspect. Biol.* **2017**, *9*, a028035.
- (3) Gonzalez-Garcia, M.; Fusco, G.; De Simone, A. Membrane Interactions and Toxicity by Misfolded Protein Oligomers. *Front. Cell Dev. Biol.* **2021**, *9*, No. 642623.
- (4) Perni, M.; Galvagnion, C.; Maltsev, A.; Meisl, G.; Müller, M. B.; Challa, P. K.; Kirkegaard, J. B.; Flagmeier, P.; Cohen, S. I.; Cascella, R.; Chen, S. W.; Limbocker, R.; Sormanni, P.; Heller, G. T.; Aprile, F. A.; Cremades, N.; Cecchi, C.; Chiti, F.; Nollen, E. A.; Knowles, T. P.; Vendruscolo, M.; Bax, A.; Zasloff, M.; Dobson, C. M. A Natural Product Inhibits the Initiation of α -Synuclein Aggregation and Suppresses its Toxicity. *Proc. Natl. Acad. Sci. U. S. A.* **2017**, *114*, E1009–E1017.
- (5) Perni, M.; Flagmeier, P.; Limbocker, R.; Cascella, R.; Aprile, F. A.; Galvagnion, C.; Heller, G. T.; Meisl, G.; Chen, S. W.; Kumita, J. R.; Challa, P. K.; Kirkegaard, J. B.; Cohen, S. I. A.; Mannini, B.; Barbut, D.; Nollen, E. A.; Cecchi, C.; Cremades, N.; Knowles, T. P. J.; Chiti, F.; Zasloff, M.; Vendruscolo, M.; Dobson, C. M. Multistep Inhibition of α -Synuclein Aggregation and Toxicity in Vitro and in Vivo by Trodusquemine. *ACS Chem. Biol.* **2018**, *13*, 2308–2319.
- (6) Limbocker, R.; Chia, S.; Ruggeri, F. S.; Perni, M.; Cascella, R.; Heller, G. T.; Meisl, G.; Mannini, B.; Habchi, J.; Michaels, T. C. T.; Challa, P. K.; Ahn, M.; Casford, S. T.; Fernando, N.; Xu, C. K.; Kloss, N. D.; Cohen, S. I. A.; Kumita, J. R.; Cecchi, C.; Zasloff, M.; Linse, S.; Knowles, T. P. J.; Chiti, F.; Vendruscolo, M.; Dobson, C. M. Trodusquemine Enhances $A\beta_{42}$ Aggregation but Suppresses its Toxicity by Displacing Oligomers from Cell Membranes. *Nat. Commun.* **2019**, *10*, 225.
- (7) Limbocker, R.; Mannini, B.; Ruggeri, F. S.; Cascella, R.; Xu, C. K.; Perni, M.; Chia, S.; Chen, S. W.; Habchi, J.; Bigi, A.; Kreiser, R. P.; Wright, A. K.; Albright, J. A.; Kartanas, T.; Kumita, J. R.; Cremades, N.; Zasloff, M.; Cecchi, C.; Knowles, T. P. J.; Chiti, F.; Vendruscolo, M.; Dobson, C. M. Trodusquemine Displaces Protein Misfolded

Oligomers from Cell Membranes and Abrogates their Cytotoxicity Through a Generic Mechanism. *Commun Biol.* **2020**, *3*, 435.

(8) Limbocker, R.; Staats, S.; Chia, S.; Ruggeri, F. S.; Mannini, B.; Xu, C. K.; Pemi, M.; Cascella, R.; Bigi, A.; Sasser, L. R.; Block, N. R.; Wright, A. K.; Kreiser, R. P.; Custy, E. T.; Meisl, G.; Errico, S.; Habchi, J.; Flagmeier, P.; Kartanas, T.; Hollows, J. E.; Nguyen, L. T.; LeForte, K.; Barbut, D.; Kumita, J. R.; Cecchi, C.; Zasloff, M.; Knowles, T. P. J.; Dobson, C. M.; Chiti, F.; Vendruscolo, M. Squalamine and Its Derivatives Modulate the Aggregation of Amyloid- β and α -Synuclein and Suppress the Toxicity of Their Oligomers. *Front Neurosci.* **2021**, *15*, No. 680026.

(9) Errico, S.; Ramshini, H.; Capitini, C.; Canale, C.; Spaziano, M.; Barbut, D.; Calamai, M.; Zasloff, M.; Oropesa-Nuñez, R.; Vendruscolo, M.; Chiti, F. Quantitative Measurement of the Affinity of Toxic and Nontoxic Misfolded Protein Oligomers for Lipid Bilayers and of its Modulation by Lipid Composition and Trodusquemine. *ACS Chem. Neurosci.* **2021**, *12*, 3189–3202.

(10) Limbocker, R.; Errico, S.; Barbut, D.; Knowles, T. P. J.; Vendruscolo, M.; Chiti, F.; Zasloff, M. Squalamine and Trodusquemine: Two Natural Products for Neurodegenerative Diseases, from Physical Chemistry to the Clinic. *Nat. Prod. Rep.* **2022**, *39*, 742–753.

(11) Errico, S.; Lucchesi, G.; Odino, D.; Muscat, S.; Capitini, C.; Bugelli, C.; Canale, C.; Ferrando, R.; Grasso, G.; Barbut, D.; Calamai, M.; Danani, A.; Zasloff, M.; Relini, A.; Caminati, G.; Vendruscolo, M.; Chiti, F. Making Biological Membrane Resistant to the Toxicity of Misfolded Protein Oligomers: a Lesson from Trodusquemine. *Nanoscale* **2020**, *12*, 22596–22614.

(12) West, C. L.; Mao, Y. K.; Delungahawatta, T.; Amin, J. Y.; Farhin, S.; McQuade, R. M.; Diwakarla, S.; Pustovit, R.; Stanisz, A. M.; Bienenstock, J.; Barbut, D.; Zasloff, M.; Furness, J. B.; Kunze, W. A. Squalamine Restores the Function of the Enteric Nervous System in Mouse Models of Parkinson's Disease. *J. Parkinson's Dis.* **2020**, *10*, 1477–1491.

(13) West, C. L.; McVey Neufeld, K. A.; Mao, Y. K.; Stanisz, A. M.; Forsythe, P.; Bienenstock, J.; Barbut, D.; Zasloff, M.; Kunze, W. A. Identification of SSRI-Evoked Antidepressant Sensory Signals by Secoding Vagus Nerve Activity. *Sci. Rep.* **2021**, *11*, 21130.

(14) Camilleri, M.; Subramanian, T.; Pagan, F.; Isaacson, S.; Gil, R.; Hauser, R. A.; Feldman, M.; Goldstein, M.; Kumar, R.; Truong, D.; Chhabria, N.; Walter, B. L.; Eskenazi, J.; Riesenber, R.; Burdick, D.; Tse, W.; Molho, E.; Robotom, B.; Bhatia, P.; Kadimi, S.; Klos, K.; Shprecher, D.; Marquez-Mendoza, O.; Hidalgo, G.; Grill, S.; Li, G.; Mandell, H.; Hughes, M.; Stephenson, S.; Vanderslui, J.; Pfeiffer, M.; Duker, A.; Shivkumar, V.; Kinney, W.; MacDougall, J.; Zasloff, M.; Barbut, D. Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial. *Ann. Intern. Med.* **2023**, *176*, 144.

(15) Hauser, R. A.; Sutherland, D.; Madrid, J. A.; Rol, M. A.; Frucht, S.; Isaacson, S.; Pagan, F.; Maddux, B. N.; Li, G.; Tse, W.; Walter, B. L.; Kumar, R.; Kremens, D.; Lew, M. F.; Ellenbogen, A.; Oguh, O.; Vasquez, A.; Kinney, W.; Lowery, M.; Resnick, M.; Huff, N.; Posner, J.; Ballman, K. V.; Harvey, B. E.; Camilleri, M.; Zasloff, M.; Barbut, D. Targeting Neurons in the Gastrointestinal Tract to Treat Parkinson's Disease. *Clin Park Relat Disord.* **2019**, *1*, 2–7.

(16) Barbut, D.; Hecksher-Sørensen, J.; Zhang, C.; Muzzio, M.; Huang, Z.; Jones, SR; Stewart, AFR; Chen, HH; Kinney, WA; Frey, WH; Fleming, Z; Clendenin, C; Baur, JA; Zemel, M; Zasloff, M 2022 (submitted for publication). *Discovery of a spermine-bile acid from mouse brain that increases insulin sensitivity.*

(17) Moore, K. S.; Wehrli, S.; Roder, H.; Rogers, M.; Forrest, J. N., Jr.; McCrimmon, D.; Zasloff, M. Squalamine: an Aminosterol Antibiotic from the Shark. *Proc. Natl. Acad. Sci. U. S. A.* **1993**, *90*, 1354–1358.

(18) Rao, M. N.; Shinnar, A. E.; Noecker, L. A.; Chao, T. L.; Feibush, B.; Snyder, B.; Sharkansky, I.; Sarkahian, A.; Zhang, X.; Jones, S. R.; Kinney, W. A.; Zasloff, M. Aminosterols from the Dogfish Shark *Squalus Acanthias*. *J. Nat. Prod.* **2000**, *63*, 631–635.

(19) Attwood, S. J.; Choi, Y.; Leonenko, Z. Preparation of DOPC and DPPC Supported Planar Lipid Bilayers for Atomic Force

Microscopy and Atomic Force Spectroscopy. *Int. J. Mol. Sci.* **2013**, *14*, 3514–3539.

(20) Shaw, K. P.; Brooks, N. J.; Clarke, J. A.; Ces, O.; Seddon, J. M.; Law, R. V. Pressure–Temperature Phase Behaviour of Natural Sphingomyelin Extracts. *Soft Matter* **2012**, *8*, 1070–1078.

(21) Biruss, B.; Dietl, R.; Valenta, C. The Influence of Selected Steroid Hormones on the Physicochemical Behaviour of DPPC Liposomes. *Chem. Phys. Lipids* **2007**, *148*, 84–90.

(22) Oropesa-Nuñez, R.; Seghezza, S.; Dante, S.; Diaspro, A.; Cascella, R.; Cecchi, C.; Stefani, M.; Chiti, F.; Canale, C. Interaction of Toxic and Non-Toxic HypF-N Oligomers with Lipid Bilayers Investigated at High Resolution with Atomic Force Microscopy. *Oncotarget.* **2016**, *7*, 44991–45004.

(23) Galvagnion, C.; Brown, J. W.; Ouberaï, M. M.; Flagmeier, P.; Vendruscolo, M.; Buell, A. K.; Sparr, E.; Dobson, C. M. Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of α -synuclein. *Proc. Natl. Acad. Sci. U. S. A.* **2016**, *113*, 7065–7070.

(24) Galvagnion, C.; Buell, A. K.; Meisl, G.; Michaels, T. C.; Vendruscolo, M.; Knowles, T. P.; Dobson, C. M. Lipid vesicles trigger α -synuclein aggregation by stimulating primary nucleation. *Nat. Chem. Biol.* **2015**, *11*, 229–234.

(25) Zhu, M.; Li, J.; Fink, A. L. The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. *J. Biol. Chem.* **2003**, *278*, 40186–40197.

(26) Demuro, A.; Mina, E.; Kaye, R.; Milton, S. C.; Parker, I.; Glabe, C. G. Calcium Dysregulation and Membrane Disruption as a Ubiquitous Neurotoxic Mechanism of Soluble Amyloid Oligomers. *J. Biol. Chem.* **2005**, *280*, 17294–17300.

(27) Diaz, J. C.; Simakova, O.; Jacobson, K. A.; Arispe, N.; Pollard, H. B. Small Molecule Blockers of the Alzheimer Abeta Calcium Channel Potently Protect Neurons from Abeta Cytotoxicity. *Proc. Natl. Acad. Sci. U. S. A.* **2009**, *106*, 3348–3353.

(28) Decker, H.; Jürgensen, S.; Adrover, M. F.; Brito-Moreira, J.; Bomfim, T. R.; Klein, W. L.; Epstein, A. L.; De Felice, F. G.; Jerusalinsky, D.; Ferreira, S. T. N-methyl-D-aspartate Receptors are Required for Synaptic Targeting of Alzheimer's Toxic Amyloid- β Peptide Oligomers. *J. Neurochem.* **2010**, *115*, 1520–1529.

(29) Alberdi, E.; Sánchez-Gómez, M. V.; Cavaliere, F.; Pérez-Samartín, A.; Zugaza, J. L.; Trullas, R.; Domercq, M.; Matute, C. Amyloid Beta Oligomers Induce Ca²⁺ Dysregulation and Neuronal Death Through Activation of Ionotropic Glutamate Receptors. *Cell Calcium* **2010**, *47*, 264–272.

(30) Fani, G.; La Torre, C. E.; Cascella, R.; Cecchi, C.; Vendruscolo, M.; Chiti, F. Misfolded Protein Oligomers Induce an Increase of Intracellular Ca²⁺ Causing an Escalation of Reactive Oxidative Species. *Cell. Mol. Life Sci.* **2022**, *79*, 500.

(31) Di Veroli, G. Y.; Fornari, C.; Goldlust, I.; Mills, G.; Koh, S. B.; Bramhall, J. L.; Richards, F. M.; Jodrell, D. I. An Automated Fitting Procedure and Software for Dose-Response Curves with Multiphasic Features. *Sci. Rep.* **2015**, *5*, 14701.

(32) Hastie, T.J.; Tibshirani, R.J. *Generalized Additive Models*. Chapman & Hall/CRC 1990. ISBN 978–0–412-34390-2.

(33) Williams, T. L.; Urbanc, B.; Marshall, K. E.; Vadukul, D. M.; Jenkins, A. T.; Serpell, L. C. Europium as an inhibitor of Amyloid- β (1–42) induced membrane permeation. *FEBS Lett.* **2015**, *589*, 3228–3236.

(34) Kumar, N.; Singh, B.; Bhandari, P.; Gupta, A. P.; Kaul, V. K. Steroidal Alkaloids from *Holarrhena Antidysenterica* (L.) WALL. *Chem. Pharm. Bull.* **2007**, *55*, 912–914.

(35) Janot, M. M.; Laine, F.; Goutarel, R. Steroid alkaloids. V. Alkaloids of *Malouetia Bequaertiana*. E. Woodson (Apocynaceae): funtuphyllamine B and malouetine. Preliminary communication. *Ann. Pharm. Fr.* **1960**, *18*, 673–677.

(36) Emanoil-Ravicovitch, R.; Franque, E. Interaction of Irehdi-amine A, a Steroid Alkaloid with the Bacteriophage Phi X 174. *C R Acad Hebd Seances Acad Sci D.* **1967**, *265*, 272–275.

(37) Zhang, X.; Rao, M. N.; Jones, S. R.; Shao, B.; Feibush, P.; McGuigan, M.; Tzodikov, N.; Feibush, B.; Sharkansky, I.; Snyder, B.;

Mallis, L. M.; Sarkahian, A.; Wilder, S.; Turse, J. E.; Kinney, W. A.; Kjærsgaard, H. J.; Michalak, R. S. Synthesis of Squalamine Utilizing a Readily Accessible Spermidine Equivalent. *J. Org. Chem.* **1998**, *63*, 8599–8603.

(38) Jones, S. R.; Selinsky, B. S.; Rao, M. N.; Zhang, X.; Kinney, W. A.; Tham, F. S. Efficient Route to 7 α -(Benzoyloxy)-3-dioxolane Cholestan-24(R)-ol, a Key Intermediate in the Synthesis of Squalamine. *J. Org. Chem.* **1998**, *63*, 3786–3789.

(39) Zasloff, M.; Williams, J. I.; Chen, Q.; Anderson, M.; Maeder, T.; Holroyd, K.; Jones, S.; Kinney, W.; Cheshire, K.; McLane, M. A Spermine-Coupled Cholesterol Metabolite from the Shark with Potent Appetite Suppressant and Antidiabetic Properties. *Int. J. Obes.* **2001**, *25*, 689–697.

(40) Copeland, R. A. *Protein-Ligand Binding Equilibria in Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis*; Wiley-VCH: 2000, pp. 76–108.

(41) Hunter, R. *Zeta Potential in Colloid Science*; Science Academic Press: 1981

(42) Sierra, M. B.; Pedroni, V. I.; Buffo, F. E.; Disalvo, E. A.; Morini, M. A. The Use of Zeta Potential as a Tool to Study Phase Transitions in Binary Phosphatidylcholines Mixtures. *Colloids Surf., B* **2016**, *142*, 199–206.

(43) Hutter, J. L.; Bechhoefer, J. Calibration of Atomic-Force Microscope Tips. *Rev. Sci. Instrum.* **1993**, *64*, 1993.

(44) Lakowicz, J. R. *Principles of Fluorescence Spectroscopy*. 2006, Springer: Berlin.

(45) Lambert, M. P.; Viola, K. L.; Chromy, B. A.; Chang, L.; Morgan, T. E.; Yu, J.; Venton, D. L.; Krafft, G. A.; Finch, C. E.; Klein, W. L. Vaccination with Soluble Abeta Oligomers Generates Toxicity-Neutralizing Antibodies. *J. Neurochem.* **2001**, *79*, 595–605.

(46) Cascella, R.; Evangelisti, E.; Bigi, A.; Becatti, M.; Fiorillo, C.; Stefani, M.; Chiti, F.; Cecchi, C. Soluble Oligomers Require a Ganglioside to Trigger Neuronal Calcium Overload. *J. Alzheimers Dis.* **2017**, *60*, 923–938.